Humanized Transgenic Mice Are Resistant to Chronic Wasting Disease Prions From Norwegian Reindeer and Moose

Jonathan D. F. Wadsworth,1,* Susan Joiner,1 Jacqueline M. Linehan,1 Kezia Jack,1 Huda Al-Doujaily,1 Helena Costa,1 Thea Ingold,1 Fuquan Zhang,1 Malin K. Sandberg,1 Sebastian Brandner,1,2 Linh Tran,3 Turid Vikøren,3 Jørn Våge,3 Malin K. Sandberg,1 Sebastian Brandner,1,2 Linh Tran,3 Turid Vikøren,3 Jørn Våge,3

1Medical Research Council Prion Unit at University College London, University College London Institute of Prion Diseases, London, United Kingdom, 2Department of Neurodegenerative Disease, University College London Queen Square Institute of Neurology and Division of Neuropathology, National Hospital for Neurology and Neurosurgery, University College London National Health Service Foundation Trust, London, United Kingdom, 3Norwegian Veterinary Institute, Oslo, Norway, and 4Norwegian Institute for Nature Research, Trondheim, Norway

Chronic wasting disease (CWD) is the transmissible spongiform encephalopathy or prion disease affecting cervids. In 2016, the first cases of CWD were reported in Europe in Norwegian wild reindeer and moose. The origin and zoonotic potential of these new prion isolates remain unknown. In this study to investigate zoonotic potential we inoculated brain tissue from CWD-infected Norwegian reindeer and moose into transgenic mice overexpressing human prion protein. After prolonged postinoculation survival periods no evidence for prion transmission was seen, suggesting that the zoonotic potential of these isolates is low.

Keywords. chronic wasting disease (CWD); moose; prion; prion disease; prion protein; reindeer; transgenic mice; transmissible spongiform encephalopathy (TSE).

Chronic wasting disease (CWD) is the transmissible spongiform encephalopathy or prion disease affecting the Cervidae family [1]. CWD is a contagious disease in free-ranging and captive cervid populations and considerable human exposure may be occurring in North America through consumption of hunted deer. Current evidence from experimental and epidemiological research suggests that the zoonotic potential of North American CWD prions is low [1, 2]; however, considerable uncertainties remain. Foremost among these is that the number of prion strains propagating CWD is ill-defined and this situation is compounded by the knowledge that novel prion strains with altered host ranges can arise as a result of prion protein (PrP) polymorphisms in both inter- and intraspecies transmissions [1–4]. Consequently, the potential public health risks of emergent CWD prions in new hosts must be evaluated directly.

Until recently, the occurrence of CWD appeared to be geographically restricted to North America and South Korea; however, from 2016 onwards CWD has been reported in Norwegian wild reindeer Rangifer tarandus [5], moose Alces alces [6], and red deer Cervus elaphus [7], with further cases in moose identified in Finland and Sweden [2]. The origin, strain properties, and zoonotic potential of these first European CWD prion isolates remain unknown; however, the neuropathological phenotypes and the molecular strain types of disease-associated, protease-resistant PrP (PrPSc) seen in affected species suggest that CWD in Norwegian reindeer has similarities to North American CWD but may not be caused by an identical strain [5, 8], whereas CWD in Norwegian moose and red deer are novel [2, 6–8]. In this study, to inform on the zoonotic potential of these isolates, we performed transmission studies of brain samples from Norwegian reindeer and moose with CWD to transgenic mice that overexpress 1 or the other of the 2 common polymorphic forms of human PrP, with either methionine (M) or valine (V) at residue 129, on a congenic mouse PrP null background. These mice are highly appropriate models to aid in the risk assessment of newly emerging animal prions as they are susceptible to classical bovine spongiform encephalopathy (BSE) prions from cattle as well as a wide range of sporadic and acquired human prion isolates [9–11].

METHODS

Research Governance

All work with cervid samples at University College London (UCL) was conducted in microbiological containment level 3 facilities with strict adherence to safety protocols. Work with mice was performed under approval and license granted by the UK Home Office (Animals (Scientific Procedures) Act 1986), project license number 70/9022, which conformed to UCL institutional guidelines and Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines (www.nc3rs.org.uk/ARRIVE/). Human tissues used in this study (Supplementary Figures 1 and 2) were obtained at autopsy with informed consent from patients or their relatives in accordance with UK legislation and the Human Tissue Authority license held by UCL Institute of Neurology. Ethical approval for using human tissues was given by the National Hospital for Neurology and Neurosurgery and the UCL Institute of Neurology Joint

Received 1 December 2020; editorial decision 14 January 2021; accepted 19 January 2021; published online 27 January 2021.

*Present affiliation: Swedish University of Agricultural Sciences, Uppsala, Sweden.

Correspondence: Jonathan Wadsworth, PhD, MRC Prion Unit at UCL, UCL Institute of Prion Diseases, 33 Cleveland Street, London W1T 7FF, UK (j.wadsworth@prion.ucl.ac.uk).

The Journal of Infectious Diseases 2022;226:933–7
© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: 10.1093/infdis/jiab033
Research Ethics Committee (references 03/N036, 03/N038, and 03/N133).

**Cervid Brain Samples**

Frozen brain samples from CWD-infected reindeer (16-04-V142) [5] and moose (16-60-P138 and 16-60-P153, moose numbers 1 and 2, respectively, in the study of Pirisinu et al) [6] and from reindeer (16-04-V176) and moose (16-60-P195) tested negative for CWD were imported from the Norwegian Veterinary Institute Oslo to UCL London under license granted by the UK Animal and Plant Health Agency (license No. ITIMP16.0426A).

**Western Blotting**

Brain samples were prepared as 10% (w/v) homogenates in Dulbecco’s sterile phosphate buffered saline lacking Ca$^{2+}$ and Mg$^{2+}$ ions (D-PBS) using Duall glass tissue grinders (Anachem) or a Precelllys Evolution tissue homogenizer (Bertin Instruments). Proteinase K (PK) digestion (50 or 100 μg/mL) was performed as described previously [12]. Samples were analyzed on Novex 16% Tris-Glycine gels (Bio-Rad Laboratories) and calibrated using the Seeblue Prestained Protein Standard from Invitrogen (Thermo Fisher Scientific). Proteinase K (PK) digestion (50 or 100 μg/mL) was performed as described previously [12].

**Transmission Studies**

Transgenic mouse brains fixed in 10% buffered formal-saline were immersed in 98% formic acid for 1 hour and paraffin wax embedded. Following further washing in 10% buffered formal-saline, tissue samples were processed and paraffin wax embedded. Serial sections of 4 μm nominal thickness were taken.

**Neuropathology and Immunohistochemistry for Detection of PrP**

Transgenic mouse brains fixed in 10% buffered formal-saline were immersed in 98% formic acid for 1 hour and paraffin wax embedded. Following further washing in 10% buffered formal-saline, tissue samples were processed and paraffin wax embedded. Serial sections of 4 μm nominal thickness were taken. Deparaffinized sections were investigated for abnormal human PrP deposition on a Ventana Discovery XT automated IHC staining machine (Roche Tissue Diagnostics) using protocols developed on a Ventana Benchmark staining machine [12].

Briefly, sections were treated with cell conditioning solution (Discovery CC1; Roche Tissue Diagnostics) at 95°C for 30 minutes followed by treatment with a low concentration of protease (Protease 3; Roche Tissue Diagnostics) for 12 minutes. Anti-PrP monoclonal antibodies 3F4 and ICSM 35 were used in conjunction with biotinylated polyclonal rabbit anti-mouse immunoglobulin secondary antibodies (Dako; Agilent) and Ventana proprietary detection reagents utilizing 3,3′-diaminobenzidine tetrahydrochloride as the chromogen (DAB Map Detection Kit; Roche Tissue Diagnostics). Conventional methods on a Gemini AS Automated Slide Stainer (Thermo Fisher Scientific) were used for hematoxylin and eosin (H&E) staining. Positive controls for the staining technique were used throughout. All slides were digitally scanned on a LEICA SCN400 instrument, and images were captured from the LEICA slidepath software and composed with Adobe Photoshop.

**RESULTS**

Cervid brain samples imported from the Norwegian Veterinary Institute were prepared as 10% (w/v) homogenates in sterile...
D-PBS and analyzed for detectable PrPSc by western blotting to access their suitability for transmission studies. While PrPSc was readily detected by direct analysis of 10 µL 10% (w/v) CWD-infected reindeer brain homogenate (Figure 1), the two 10% (w/v) CWD-infected moose brain homogenates had lower relative levels of PrPSc (approximately 10- or 50-fold less than reindeer brain homogenate) that required NaPTA precipitation from a larger volume (100 µL) for reliable detection (Figure 1). Despite lower levels of PrPSc, these moose brain homogenates are highly appropriate for transmission studies as peripheral tissues from animals with CWD, that would most likely be consumed by humans, typically contain PrPSc at concentrations orders of magnitude lower than present in the central nervous system [13].

PrPSc-positive 10% (w/v) CWD-infected reindeer and moose brain homogenates were diluted to 1% (w/v) with sterile D-PBS and 30 µL inoculated intracerebrally into groups of 129MM Tg35c mice and 129VV Tg152c mice. Mice were then examined daily over postinoculation periods up to 700 days and killed if they were exhibiting signs of distress or if a diagnosis of clinical prion disease was established. To determine whether recipient mice had become prion infected, frozen brain samples were prepared as 10% (w/v) brain homogenates in D-PBS and analyzed for detectable PrPSc by NaPTA precipitation and high-sensitivity western blotting, and fixed brain samples were analyzed for neuropathological changes and abnormal PrP deposition by IHC.

Despite prolonged postinoculation periods extending up to 700 days, Norwegian CWD prion isolates produced no clinical prion disease, or biochemical evidence (Supplementary Figure 1) or histopathologic evidence (Supplementary Figure 2) for subclinical prion infection in any inoculated mouse (Table 1). The lack of detection of disease-related PrP in the brains of inoculated mice by either high-sensitivity immunoblotting or IHC indicates that both the methionine and valine 129 polymorphs of human PrP are highly resistant to pathological conversion by CWD prions from these Norwegian reindeer and moose.

**DISCUSSION**

The zoonotic transmission of BSE prions from cattle has dramatically highlighted the potential risk posed to humans from dietary exposure to animal prions. In this study we found that transgenic mice overexpressing 1 or the other of the 2 common residue 129 polymorphic forms of human PrP, which are susceptible to cattle BSE prions, are highly resistant to infection with recently identified CWD prions from Norwegian reindeer and moose. These data are congruent with previous findings that our human PrP transgenic mice are highly resistant to infection with North American CWD prions from mule deer [14] and with other studies using different lines of humanized transgenic

---

**Figure 1.** Immunoblot analyses of CWD-negative and CWD-infected Norwegian reindeer and moose brain. A and B, Immunoblots of brain homogenates analyzed with anti-PrP monoclonal antibody ICSM 35 and high-sensitivity enhanced chemiluminescence. A, Brain homogenates, 10% (w/v), from a CWD-negative reindeer (16-04-V178; normal) and CWD-infected reindeer (16-04-V142; CWD) analyzed before (−) or after (+) digestion with PK (50 µg/mL final protease concentration, 1 hour, 37°C). The provenance of the brain sample is designated above each lane. Loading volumes for the immunoblot were 2.5 µL of PK− and 10 µL of PK+ 10% (w/v) brain homogenate. B, Brain homogenates, 10% (w/v), from a CWD-negative moose (16-60-P195; normal), and CWD-infected moose (16-60-P153 and 16-60-P138; CWD). The provenance of the brain sample is designated above each lane. Samples were analyzed with (+) or without (−) PK digestion (50 µg/mL final protease concentration, 1 hour, 37°C) and with (+) or without (−) preconcentration by NaPTA precipitation (from 100 µL 10% (w/v) brain homogenate). The volume equivalent of 10% (w/v) brain homogenates loaded for the immunoblots was 5 µL of PK−/NaPTA−, 5 µL of PK+/NaPTA−, and 100 µL of PK+/NaPTA+. The normal cellular isoform of PrP (PrPC) present in both normal and CWD-infected brain homogenate is completely degraded by PK, whereas the scrapie or disease-associated isoform of PrP (PrPSc) comprises aggregated assemblies with the C-terminal two-thirds of the protein showing marked resistance to proteolytic degradation, generating 3 bands corresponding to N-terminally truncated fragments of di-, mono-, and nonglycosylated PrP. The concentration of PrPSc in 10% (w/v) brain homogenate from CWD-infected moose 16-60-P138 was about 5-fold higher than CWD-infected moose 16-60-P138. Exposure times were varied to show comparable signal strength. Abbreviations: CWD, chronic wasting disease; NaPTA, sodium phosphotungstic acid; PK, proteinase K; PrP, prion protein.

---

BRIEF REPORT • JID 2022:226 (1 September) • 935
mice that showed no prion transmission after challenge with North American CWD isolates derived from elk, mule deer, or white-tailed deer (reviewed in reference [2]). Although certain North American CWD isolates appear to have the capacity to seed the misfolding of human PrP in vitro (see reference [2] for review), in vivo studies performed with humanized mice and macaques are considered to be the most pertinent models of human susceptibility [2].

The apparent inability of prions from Norwegian reindeer and moose to propagate in intracerebrally inoculated transgenic mice overexpressing human PrP is reassuring and suggests that the potential zoonotic threat from the new European isolates investigated here is low and not overtly dissimilar to any of the North American CWD isolates so far examined in humanized transgenic mouse models [2]. However, determining whether transmission barriers in our mice are absolute will now require secondary passage of brain homogenates from “negative” challenged mice from this experiment in further transgenic mice. In addition, because splenic PrP expression levels in our transgenic mice are low, we did not collect this tissue for analyses. Findings in spleen from ongoing bioassays of both Norwegian and North American CWD isolates in other lines of humanized transgenic mouse models [2]. However, determining whether transmission barriers in our mice are absolute will now require secondary passage of brain homogenates from “negative” challenged mice from this experiment in further transgenic mice. In addition, because splenic PrP expression levels in our transgenic mice are low, we did not collect this tissue for analyses. Findings in spleen from ongoing bioassays of both Norwegian and North American CWD isolates in other lines of humanized transgenic mouse will be important to see whether lymphoid tissue expressing human PrP is permissive to CWD prion replication [2]. Finally, because polymorphisms of PrP can dictate prion strain selection [1–4], and reindeer PrP in particular is highly polymorphic [15], it will be of critical importance to evaluate the zoonotic potential of further European CWD cases with novel neuropathological features or divergent PrP genotypes as they emerge.

Supplementary Data
Supplementary materials are available at The Journal of Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Notes
Acknowledgments. We thank our biological services team for animal care and R. Newton for preparation of figures. We are very grateful to patients and their families for generously consenting to use of human tissues in this study.

Financial support. This work was supported by the Norwegian Ministry of Agriculture (Norwegian Chronic Wasting Disease Surveillance Program grant to Norwegian Veterinary Institute and Norwegian Institute for Nature Research); Norwegian Veterinary Institute (grant number 12081-CWD); and the Medical Research Council, UK (grant numbers MC_U123160655 and MC_UU_00024/5 to University College London).

Potential conflict of interests. J. C. is a director and J. C. and J. D. F. W. are shareholders of D-Gen, Ltd, an academic spin-out company working in the field of prion disease diagnosis, decontamination, and therapeutics. D-Gen supplied the ICSM 35 antibody used in this study. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References
1. Benestad SL, Telling GC. Chronic wasting disease: an evolving prion disease of cervids. Handb Clin Neurol 2018; 153:135–51.
2. EFSA Panel on Biological Hazards (BIOHAZ). Update on chronic wasting disease (CWD) III. EFSA J 2019; 17:e05863.
3. Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 2016; 539:217–26.

Table 1. Survival Times of Human PrP-Expressing Transgenic Mice Inoculated With CWD Prions From Norwegian Reindeer and Moose

| Inocula | Transmission | 129MM Tg35c Mice | 129VV Tg152c Mice |
|---------|--------------|----------------|-------------------|
| Prion Agent | Source Code | Attack Rate* | Survival, d⁰ | Attack Rate* | Survival, d⁰ |
| Reindeer CWD | 16-04-V142 | 0/19 | 373, 391, 457, 509, 518, 523, 630–700 (13) | 0/17 | 498, 513, 519, 553, 567, 629–700 (12) |
| Moose CWD | 16-60-P138 | 0/20 | 210, 258, 263, 390, 425, 428, 441, 475, 502, 524, 533, 566, 587, 634–700 (7) | 0/20 | 253, 370, 378, 454, 539, 592, 600–700 (14) |
| Moose CWD | 16-60-P153 | 0/19 | 409, 423, 553, 601–700 (16) | 0/19 | 464, 482, 526, 539, 539, 589, 596, 609–700 (12) |

Abbreviations: CWD, chronic wasting disease; PrP, prion protein.
*Groups of 20 mice were inoculated intracerebrally with 30 µL of 1% (w/v) brain homogenate. Attack rate is defined as the total number of both clinically affected and subclinically infected mice as a proportion of the number of inoculated mice. Subclinical prion infection was assessed by immunohistochemical examination of brain for abnormal PrP deposition and by sodium phosphotungstic acid precipitation of 250 µL 10% (w/v) brain homogenate and analysis for protease-resistant PrP by proteinase K digestion and immunoblotting.
⁰The interval between inoculation and culling due to intercurrent illness, senescence, or termination of the experiment at 700 days postinoculation. Death dates of individual mice are shown together with the range for mice surviving beyond 600 days with the number of mice in this range shown in parentheses. Mice culled with postinoculation periods of ≤ 200 days due to intercurrent illness (all confirmed negative for subclinical prion infection) were not included in calculating attack rates.
4. Mead S, Lloyd S, Collinge J. Genetic factors in mammalian prion diseases. Annu Rev Genet 2019; 53:117–47.
5. Benestad SL, Mitchell G, Simmons M, Ytrehus B, Vikøren T. First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer. Vet Res 2016; 47:88.
6. Pirisinu L, Tran L, Chiappini B, et al. Novel type of chronic wasting disease detected in moose (Alces alces), Norway. Emerg Infect Dis 2018; 24:2210–8.
7. Vikøren T, Våge J, Madslien KI, et al. First detection of chronic wasting disease in a wild red deer (Cervus elaphus) in Europe. J Wildl Dis 2019; 55:970–2.
8. Nonno R, Di Bari MA, Pirisinu L, et al. Studies in bank voles reveal strain differences between chronic wasting disease prions from Norway and North America. Proc Natl Acad Sci U S A 2020; 117:31417–26.
9. Wadsworth JD, Asante EA, Collinge J. Contribution of transgenic models to understanding human prion disease. Neuropathol Appl Neurobiol 2010; 36:576–97.
10. Wadsworth JD, Joiner S, Linehan JM, et al. Atypical scrapie prions from sheep and lack of disease in transgenic mice overexpressing human prion protein. Emerg Infect Dis 2013; 19:1731–9.
11. Asante EA, Smidak M, Grimshaw A, et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature 2015; 522:478–81.
12. Wadsworth JDF, Adamson G, Joiner S, et al. Methods for molecular diagnosis of human prion disease. Methods Mol Biol 2017; 1658:311–46.
13. Gavin C, Henderson D, Benestad SL, Simmons M, Adkin A. Estimating the amount of chronic wasting disease infectivity passing through abattoirs and field slaughter. Prev Vet Med 2019; 166:28–38.
14. Sandberg MK, Al-Doujaily H, Sigurdson CJ, et al. Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. J Gen Virol 2010; 91:2651–7.
15. Güere ME, Våge J, Tharaldsen H, et al. Chronic wasting disease associated with prion protein gene (PRNP) variation in Norwegian wild reindeer (Rangifer tarandus). Prion 2020; 14:1–10.